Showing results (11-20 of 113) with videos related to
Sort By:
Pageof 12
Genes, Chromosomes & Cancer|December 6, 2017
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applicationsAnna-Lena Volckmar, Holger Sültmann, Anja Riediger, et al.Plos One|June 10, 2011
Evidence for a role of srGAP3 in the positioning of commissural axons within the ventrolateral funiculus of the mouse spinal cordClaire Bacon, Volker Endris, Irwin Andermatt, et al.International Journal of Molecular Medicine|September 10, 2015
Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissueJana Fassunke, Florian Haller, Simone Hebele, et al.Cold Spring Harbor Molecular Case Studies|September 15, 2016
Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemiaTilmann Bochtler, Stefan Fröhling, Wilko Weichert, et al.Cell Death Discovery|June 30, 2017
The bile acid receptor FXR attenuates acinar cell autophagy in chronic pancreatitisXiaodong Zhou, Li Xie, Frank Bergmann, et al.Oncoimmunology|December 8, 2018
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenJan Budczies, Anja Seidel, Petros Christopoulos, et al.International Journal of Cancer|July 13, 2017
Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomasSteffen Dietz, Alexander Harms, Volker Endris, et al.Oncotarget|June 21, 2016
Molecular driver alterations and their clinical relevance in cancer of unknown primary siteHarald Löffler, Nicole Pfarr, Mark Kriegsmann, et al.Oncotarget|October 10, 2014
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differencesMark Kriegsmann, Volker Endris, Thomas Wolf, et al.BMC Cancer|October 29, 2020
The majority of β-catenin mutations in colorectal cancer is homozygousAlexander Arnold, Moritz Tronser, Christine Sers, et al.Pageof 12